| Identification | Back Directory | [Name]
ASS234 | [CAS]
1334106-34-1 | [Synonyms]
ASS234
ASS234,ASS-234
1H-Indole-2-methanamine, N,1-dimethyl-5-[3-[1-(phenylmethyl)-4-piperidinyl]propoxy]-N-2-propyn-1-yl- | [Molecular Formula]
C29H37N3O | [MOL File]
1334106-34-1.mol | [Molecular Weight]
443.62 |
| Chemical Properties | Back Directory | [Boiling point ]
582.5±45.0 °C(Predicted) | [density ]
1.05±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
powder | [pka]
8.96±0.10(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
ASS234 is a potent monoamino oxidase (MAO) inhibitor with IC50s of 5.2 nM and 43 nM for MAO-A and MAO-B, respectively. ASS234 also inhibits AChE and BuChE with IC50s of 350 nM and 460 nM, respectively[1]. | [Biological Activity]
ASS234 is a brain-penetrant and orally active multi-target small molecule (MTSM) against (acetyl & butyryl) cholinesterases (hAChE/hBuChE IC50 = 0.81/1.82 μM)monoamine oxidases (hMAO-A/B IC50 = 0.27/120 nM)histamine H3 receptor (hH3R Ki = 84.2 nM; hH4R Ki >10 μM) and sigma-1/2 receptors (hS1R/rS2R = 2.82/50.3 nM). ASS234 exhibits antioxidative and neuroprotective effects in SH-SY5Y cultures (5 μM) and demonstrates therapeutic efficacy in neurodegerative disease models in vivo via sc. (0.62 mg/kg/d mice; 5 mg/kg rats)ip. (1 mg/kg mice) or po. (1 & 10 mg/kg mice). | [Enzyme inhibitor]
he multi-target enzyme inhibitor (FW = g/mol), also known as N-((5-(3- (1-benzylpiperidin-4-yl)propoxy)-1-methyl-1H-indol-2-yl)methyl)-N- methylprop-2-yn-1-amine, bears the MAO-inhibiting propargyl group attached to a cholinesterase-inhibiting donepezil moiety retains the ability to inhibit human acetyl- and butyryl-cholinesterases as well as monamine oxidases. With a kinact/KI value of 3 × 106 min? 1 M? 1 , ASS234 inhibition of MAO A and MAO B by ASS234 is almost as effective as clorgyline. It also forms the same N5 -adduct with the isoalloxazine ring of the FAD cofactor. The kinetic studies demonstrate that ASS234 is not only a reversible inhibitor of both acetyl and butyryl-cholinesterases with μM affinity, but is also a highly potent irreversible inhibitor of MAO A similarly to clorgyline. | [IC 50]
MAO-A: 5.2 nM (IC50); MAO-B: 43 nM (IC50); AChE: 350 nM (IC50); BChE: 460 nM (IC50) | [References]
[1] Anna Stasiak, et al. Effects of novel monoamine oxidases and cholinesterases targeting compounds on brain neurotransmitters and behavior in rat model of vascular dementia. Curr Pharm Des. 2014;20(2):161-71. DOI:10.2174/13816128113199990026 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|